Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,224

Document Document Title
WO/2024/117225A1
The present invention relates to a peptide compound represented by general formula (1) [wherein: R1 represents an (S)-sec-butyl group, a benzyl group or an isopropyl group; R2 represents an (S)-sec-butyl group, a benzyl group or an isopr...  
WO/2024/081692A1
Compounds described herein are mithramycin (MTM) oxide (OX) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.  
WO/2024/030976A2
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of active agents conjugated to ligands for increased crossing of the blood brain barrier.  
WO/2024/031008A2
siRNA molecules targeting AGT mRNA that reduce or inhibit AGT production are provided. Pharmaceutical compositions containing such siRNA molecules also are provided, together with methods of their use for treating hypertension. Pharmaceu...  
WO/2023/235232A2
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...  
WO/2023/209186A1
The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.  
WO/2023/205642A2
Disclosed herein are methods and systems for engineering glycosylation. The methods and systems may use structure of sequence information of biomolecules to predict glycosylation features. The methods and systems may employ one or more t...  
WO/2023/178421A1
The present document describes antibodies or antigen-binding fragments that bind specifically to a target antigen, wherein the antibodies or antigen-binding fragments comprise complementarity determining regions (CDR1, CDR2 and CDR3) and...  
WO/2023/161962A1
The present invention relates to Muramyl dipeptide compounds having adjuvant activity. The present invention also discloses the process for the preparation of Muramyl dipeptide compound and their intermediates. The immuno-modulating prop...  
WO/2023/141855A1
Provided herein is a protein conjugate with multiple payloads and methods for making the same.  
WO/2023/143374A1
The present invention relates to a ligand, a method for preparing same, and a use thereof. The ligand has a structure represented by formula (I) or formula (II), wherein R1, R2, R3, and R4 are all linear structures with a glycosyl group ...  
WO/2023/121483A1
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...  
WO/2023/097374A1
Provided herein are metal-organic framework (MOF) biocomposites, in particular biocomposites comprising partially embedded biomolecules such as antibodies. Also provided herein are methods of producing the MOF biocomposites, and uses of ...  
WO/2023/077447A1
Disclosed are a cyclopeptide glass and a pharmaceutical composition glass containing a cyclopeptide. The cyclopeptide glass of the present invention can simultaneously exert efficacy and a drug adjuvant function. Compared with crystals a...  
WO/2023/065137A1
The present disclosure provides a protein conjugate, comprising a protein and an oligosaccharide, wherein the oligosaccharide comprises Formula (1) : wherein, the GlcNAc is directly or indirectly linked to an amino acid of the protein, t...  
WO/2023/058527A1
A compound represented by formula (1) [in formula (1): Xaa, Xaa1, Xaa2 and Xaa3 independently represent an arbitrary amino acid residue; n represents an integer of 1-20; R is nil or represents a straight-chain or branched sugar chain con...  
WO/2023/023031A2
Described herein are peptide oligonucleotide complexes comprising peptides and variants thereof as well as conjugated to, linked to, or fused to agents, wherein the peptide oligonucleotide complexes are capable of binding TfR and that ar...  
WO/2022/268939A1
The present invention relates to peptides, their use in the treatment, amelioration or prevention of chronically active autoimmune inflammation, in particular rheumatoid arthritis, and to pharmaceutical compositions comprising the same.  
WO/2022/266758A1
Provided herein are compounds including a linear polyglycerol, a peptide tag, with either a linker-sugar-sialic acid moiety or a sulfate group, a preservation solutions including the compounds, methods for using the compounds or the pres...  
WO/2022/270482A1
The present invention provides: sugar chain immobilized polymer particles in which a hydrophobized sugar chain polypeptide is firmly immobilized to the outermost surface of the polymer particles and the sugar chain density on the surface...  
WO/2022/255289A1
The present invention relates to a method for producing a glycopeptide, the method including a step for modifying an Fc region of an avian antibody, and a step for lysing the modified Fc region using a proteolytic enzyme, and the glycope...  
WO/2022/245553A2
The present invention is related to the field of pulmonary therapeutics. In particular, the compositions described herein are used in methods of treating lung disease and injury including but not limited to acute respiratory distress syn...  
WO/2022/226083A1
Disclosed herein are glycan-coated RBD immunogens, engineered nanoparticle vaccines comprising glycan-coated RBD immunogens and methods of use thereof for SARS-CoV-2 vaccines.  
WO/2022/224015A1
An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/y...  
WO/2022/177913A1
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a mesothelin polypeptide. For example, binders (e.g., antibodies, ...  
WO/2022/150924A1
Carbohydrate of Formula (A) where R1 is H and n an integer from 1 to 5, is synthesized by reacting, under heating, compound (A0) with HO-(CH2)n-CH=CH2 in the presence of an acid capable of liberating a proton, and cooling the reaction mi...  
WO/2022/155289A1
This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide...  
WO/2022/148816A1
This invention relates to the inhibition of the proliferation and/or activation of T cells by full-length factor V (FV) protein and peptides derived from full-length FV protein. This may be used to exert an immunosuppressive effect in th...  
WO/2022/148868A1
An optimized method for synthesizing dalbavancin is provided in which an organic antisolvent such as tert-butyl methyl ether (TBME) or dimethoxyethane (DME) is used to precipitate the product of the esterification of A-40926.  
WO/2022/119917A1
The present invention provides compositions and methods useful in the diagnosis and treatment of a variety of cognitive impairments including vascular cognitive impairment and dementia, and Alzheimer's Disease. In one particular embodime...  
WO/2022/109327A1
Methods for measuring disialylated Fc glycan in a biological sample are described.  
WO/2022/093684A1
It has been discovered that phosphorylation-dependent uncoupling of endothelial nitric oxide synthase (eNOS) plays an important role in endothelial cell (EC) barrier disruption. Compositions and methods to reduce or prevent eNOS uncoupli...  
WO/2022/037665A1
The present disclosure provides a site-specific protein conjugate and the method for preparation of the same. The protein conjugate comprising a protein and an oligosaccharide, wherein said oligosaccharide comprises (I) wherein: said Glc...  
WO/2021/228853A1
The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.  
WO/2021/216323A1
A series of vancomycin C-terminus guanidine modifications are disclosed that improve antimicrobial activity, enhance the durability of antimicrobial action against selection or induction of resistance, and provide two synergistic mechani...  
WO/2021/202208A1
Embodiments of methods are disclosed for inhibiting, regulating and/or otherwise affecting or managing the pri-miR- 17-92 cluster, and certain pre-miRNA's embedded in the cluster as well as the pre-miRNA's themselves as isolated forms, a...  
WO/2021/202621A2
The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which c...  
WO/2021/179081A1
The present document describes methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I ...  
WO/2021/153687A1
Disclosed is a nucleic acid complex represented by formula (I) or a pharmaceutically acceptable salt thereof (X is CH2 or O; Y is a sugar ligand having mannose or GalNac; n is an integer of 1 to 8; and Z is a group containing an oligonuc...  
WO/2021/146812A1
The present document describes uses and methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general f...  
WO/2021/084552A1
The present invention relates to liposomally bound novel peptide fragments complexed with one or more TLR1/2 and TLR9 ligands useful as vaccine against tuberculosis and for enhancing BCG vaccine efficacy upon concomitant use.  
WO/2021/081420A2
Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic m...  
WO/2021/068080A1
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...  
WO/2021/067741A1
The present disclosure describes a CD4+ T cell repertoire that recognizes a glycopeptide epitope on gp120 presented by a MHCII pathway. The present disclosure provides gp120 glycopeptides that are capable of inducing specific humoral and...  
WO/2021/056098A1
Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier pro...  
WO/2021/060980A1
Provided herein are lipidated glycopeptide compounds of formula (I); or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. R1 is a lipid, R2 is -H or a lipid, and R3 and R4 are as defined herein. These compoun...  
WO/2021/046139A1
Methods for analysis of a glucuronide ligand-drug conjugate are provided.  
WO/2020/229982A1
The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in...  
WO/2020/222100A1
Method for purifying at least one lipoglycopeptide antibiotic comprising the steps of: i) dissolving said at least one lipoglycopeptide antibiotic in an aqueous solution to form a mixture, ii) loading said mixture into a chromatographic ...  
WO/2020/182203A1
Disclosed is a separation and purification method for a vancomycin analogue (I). The method comprises: using a vancomycin crude product as a raw material, firstly using polymer matrix chromatography packing for enrichment, and then perfo...  

Matches 1 - 50 out of 1,224